

Interleukin-10 and Interleukin-1 receptor antagonists increase during cardiac surgery

Takae Kawamura MD, PHD, Reiji Wakusawa MD, PHD,
Katsuya Inada PHD

Background: It has been reported that inflammatory cytokines such as interleukin-8 and 6 (IL-8, IL-6) increase during cardiac surgery and cause postoperative cardiac dysfunction. Therefore, it is important to investigate changes of suppressive cytokines such as IL-10, interleukin-4 (IL-4) and interleukin-1 receptor antagonist (IL-1ra) during cardiac surgery.

Method: Serum levels of cytokines and IL-1ra were measured in 10 patients during cardiac surgery with cardiopulmonary bypass. Six blood samples were drawn after inducing anaesthesia. In each sample, serum IL-10, IL-4, IL-8, IL-6 and IL-1ra were measured by enzyme linked immunosorbent assay.

Results: Serum IL-6 and IL-8 concentration (19.1 ± 8.8 pg·ml⁻¹, and 13.4 ± 5.2 pg·ml⁻¹, preoperatively) increased to 227.5 ± 191 pg·ml⁻¹ and 81.0 ± 56 pg·ml⁻¹ at 60 min after declamping the aorta ($P < 0.01$, respectively). Serum IL-10 concentration increased at 60 min after declamping the aorta compared with the preoperative value (from 1.0 ± 0 pg·ml⁻¹ to 552.0 ± 158 pg·ml⁻¹ $P < 0.001$). Similarly, serum IL-1ra concentration increased from the preoperative value of 1331 ± 896 pg·ml⁻¹ to 43353 ± 12812 pg·ml⁻¹ at 60 min after declamping the aorta ($P < 0.001$). Positive correlations were obtained between IL-10 and IL-8, and between IL-10 and IL-6 ($\gamma = 0.7$, $\gamma = 0.8$, $P < 0.001$, respectively).

Conclusion: These findings demonstrate that pro- and anti-inflammatory cytokines increase to maintain their balance during cardiac surgery.

Objectif : On a rapporté que la concentration des cytokines de l'inflammation comme les interleukines 6 et 8 (IL-8, IL-6) s'élevaient pendant la chirurgie cardiaque et provoquaient des dérangements cardiaques postopératoires. Il est donc aussi important d'examiner les perturbations produites par les cytokines suppressives comme IL-10, interleukine-4 (IL-4) et de l'antagoniste du récepteur de l'interleukine-1 (IL-1ra) pendant la chirurgie cardiaque.

Méthodes : La concentration sérique des cytokines et de IL-1ra a été mesurée chez dix patients pendant une chirurgie cardiaque sous CEC. Six échantillons de sang ont été prélevés après l'induction de l'anesthésie. Dans chacun des échantillons, on a titré IL-10, IL-4, IL-8, IL-6 et IL-1ra avec l'épreuve de l'immuno-absorption enzymatique.

Résultats : Les concentrations de IL-6 et de IL-8 (valeurs préopératoires : $19,1 \pm 8,8$ pg·ml⁻¹ et $13,4 \pm 5,2$ pg·ml⁻¹) ont augmenté à $227,45 \pm 191$ pg·ml⁻¹ et $81,0 \pm 56$ pg·ml⁻¹ 60 min après le déclampage de l'aorte (respectivement $P < 0,01$). La concentration sérique de IL-10 a augmenté 60 min après le déclampage de l'aorte comparativement aux valeurs préopératoires (de $1,0 \pm 0$ pg·ml⁻¹ à 552 ± 158 pg·ml⁻¹, $P < 0,001$). De la même façon, la concentration sérique de IL-1ra a augmenté de la valeur préopératoire de 1331 ± 896 pg·ml⁻¹ à 43353 ± 12812 pg·ml⁻¹ 60 min après le déclampage ($P < 0,001$). La corrélation était positive entre IL-10 et IL-8 et entre IL-10 et IL-6 (respectivement $\gamma = 0,7$, $\gamma = 0,8$, $P < 0,001$).

Conclusion : Ces données montrent que les cytokines pro- et anti-inflammatoires augmentent pour maintenir leur équilibre pendant la chirurgie cardiaque.

From the Department of Anaesthesiology, School of Medicine, Iwate Medical University, 19-1, Uchimaru, Morioka, Iwate 020 Japan
Address correspondence to: Takae Kawamura MD, Tel.81-196-51-5111; FAX.81-196-23-4112.
Accepted for publication September 20, 1996.

CARDIAC surgery leads to a well recognized pro-inflammatory response. This response has been demonstrated by an increase in plasma pro-inflammatory cytokines. These include TNF- α , IL-1, IL-6 and IL-8.^{1,2}

Inflammatory cytokines (IL-1, TNF, IL-6, IL-8 etc), which are produced from monocytes, macrophages or endothelial cells, have been reported to play an important role in the interaction between neutrophils and vascular endothelium.³ In a previous study, we found that IL-8 and IL-6 increased after declamping of the aorta and that there were positive correlations between IL-8 and CK-MB, and between IL-6 and CK-MB.² These results suggested that these cytokines participate in reperfusion injury. It is therefore important to determine whether IL-10, IL-4, and IL-1ra, which are potent inhibitors of pro-inflammatory cytokines⁴⁻⁸ increase. IL-10 is a recently characterized cytokine⁴ that has been implicated in the regulation of lymphoid and myeloid cells⁵ function because of its ability to suppress the synthesis of inflammatory cytokines from T cells and monocytes-macrophages.⁶ On the other hand, IL-4, defined as B cell stimulating factor, has been found to be a potent down-regulator of human monocyte-macrophage functions such as production of cytokines.^{7,8} In this study, we observed changes of IL-10 and IL-4, which are potent inhibitor of inflammatory cytokines such as IL-8 and IL-6, during cardiac surgery. In addition, we also observed changes of IL-1ra because IL-10 has been reported to up-regulate IL-1ra.

Methods

With institutional approval and informed consent, we studied 10 patients undergoing elective cardiac surgery. Preanaesthetic medications included 0.2 mg.kg⁻¹ diazepam, 1 mg.kg⁻¹ hydroxyzine, 1 mg.kg⁻¹ meperidine and 0.01 mg.kg⁻¹ atropine *im*. Anaesthesia was induced with 30 μ g.kg⁻¹ fentanyl, and tracheal intubation was facilitated with 0.15 mg.kg vecuronium. Anaesthesia was maintained using oxygen, and a high-dose of fentanyl (total 100 μ g.kg⁻¹). Ventilation was controlled to maintain PaCO₂ at approximately 40 mmHg. The perfusion apparatus included a Hollow fibre membrane oxygenator (Termo, Capiox) and non-pulsatile roller-pump (Pemco Inc). A mixture of 20% mannitol, 7% sodium bicarbonate, electrolyte solution, and CPD-added preserved blood was primed, and then perfused at a flow rate of 2.4 l.min⁻¹. Haematocrit levels were maintained at 20% or more throughout CPB. Body temperature was cooled to <30°C. All CPB was performed under mild hypothermia (30°C) with cold blood cardioplegia antegrade/retrograde myocardial

preservation. Cardioplegic arrest was induced with cold blood cardioplegia via the antegrade (ascending aortic) route until arrest was achieved. Proximal aortic-saphenous anastomoses were performed with aortic perfusion and partial occluding clamp. The ECG, EEG, and oesophageal and rectal temperatures were monitored continuously. Arterial blood oxygen saturation was also monitored continuously with a pulse oximeter (Datex, Satlite), and end tidal carbon dioxide concentrations with capnography (Datex, Capnomac). A catheter was placed in the radial artery to measure direct arterial pressure, and from which blood samples were drawn. Six blood samples were drawn after inducing anaesthesia, at the following times: before operation, before starting CPB, 60 min after aortic occlusion, and 60, 120 and 180 min after declamping the aorta. In each sample, serum IL-10, IL-4, IL-8, IL-6 and IL-1ra concentrations were measured by enzyme linked immunosorbent assay (ELISA) kits (IL-10: BioSource International, Camarillo, CA, USA, IL-4: Medgenix Diagnostics SA, Belgium, IL-8: R&D systems, Minneapolis, MN, USA, IL-6: Toray Fujibionics Inc, Tokyo, Japan, IL-1ra: Amersham International plc, UK.) The minimum detection limits of these assays for IL-10, IL-4, IL-8, IL-6 and IL-1ra were 5, 2, 3, 10 and 22 pg.ml⁻¹. The coefficients of variation of these assays for IL-10, IL-4, IL-8, IL-6 and IL-1ra were all less than 10%.

For statistical analysis, repeated measures ANOVA was used for serial measurement. Significant difference was defined as P<0.05.

Results

The patient's age, body weight, ejection fraction, CPB time, and aortic clamp time are shown in Table I. Serum IL-10 concentration (1 \pm 0 pg.ml⁻¹ preoperatively) peaked at 552 \pm 158 pg.ml⁻¹ at 60 min after

TABLE I Clinical characteristics

Patient	Age	Weight	Diag	CPB	A ^o clamp	EF
	yr	kg		min	min	%
1	68	67.5	AP	190	128	75
2	58	65	AP	129	65	60
3	72	35	AR	98	66	55
4	71	61	AP	142	70	66
5	36	75	AA,AR	257	142	69
6	55	52	MR	112	80	69
7	16	61	AR,MR	185	150	40
8	50	60	AP	139	82	30
9	50	60	AP	139	82	30
10	68	64	AP	195	114	48
Mean	54	62		159	101	55
SD	17	11.6		47.4	32.6	15.1

Diag diagnosis; CPB cardiopulmonary bypass time; A^oclamp aortic clamp time; EF ejection fraction; AP angina pectoris; AR aortic regurgitation; MR mitral regurgitation; AA aortic aneurysm




FIGURE 1 Changes of serum interleukin-10 concentration at the following sampling points. (1) before operation, (2) pre-CPB, (3) 60 min after aortic occlusion, (4) 60 min after declamping of aorta, (5) 120 min after declamping of aorta, (6) 180 min after declamping of aorta.

Mean±SE, ★*P*<0.001 vs (1), (3)




FIGURE 2 Changes of serum interleukin-1 receptor antagonist concentration at each time sampling point.

Mean±SE, ★*P*<0.001 vs (1), (3)

TABLE II Serum interleukin concentrations at each time.

	Sampling times					
	1	2	3	4	5	6
IL-8 pg·ml ⁻¹	13.4±5.2	16±4.4	36.2±29.6	81.0±56.0*	68.6±51.0*	61.3±42.8*
IL-6 pg·ml ⁻¹	19.1±8.8	13.2±10.2	16.9±10.7	227.5±191.0*	204.3±209.6*	182.8±160.8*
IL-10 pg·ml ⁻¹	1.0±0.0	1.9±1.8	11.3±14.5	552.0±158.9*	327.3±204.9*	174.2±182.7*
IL-4 pg·ml ⁻¹	2.4±2.0	2.7±3.0	2.4±3.9	6.1±4.7	18.9±41.8	7.3±7.8

Sampling times: 1) before operation, 2) pre-CPB, 3) 60 min after aortic clamping, 4) 60 min after declamping aorta, 5) 120 min after declamping aorta, 6) 180 min after declamping aorta.

Mean±SD. **P* < 0.001 vs 1) and 3).




FIGURE 3 Changes of serum interleukin-6 (left) and interleukin-8 (right) at each sampling point.

Mean±SE: ★*P*<0.001 vs (1), (3)

declamping of the aorta (*P*<0.001) and remained elevated at 174±182 pg·ml⁻¹ 180 min after declamping of the aorta (*P*<0.001, Figure 1). The levels of IL-10 at 60, 120, 180 min after declamping the aorta were higher than before surgery and at 60 min after aortic occlusion (*P*<0.001, Figure 1). Serum IL-4 did not change (Table II). Serum IL-1ra concentration increased from 60 min after declamping the aorta compared with the preoperative and the 60 min after aortic occlusion levels and peaked 180 min after declamping the aorta (*P*<0.001, Figure 2).

Serum IL-8 and IL-6 concentrations increased at 60 min after declamping the aorta and remained at a high level until 180 min after declamping the aorta (*P*<0.001, Table II, Figure 3). Furthermore, the levels of IL-8 and IL-6 at 60, 120, 180 min after declamping of the aorta were higher than that at 60 min after aortic occlusion (*P*<0.001, Table II, Figure 3). Regression analysis demonstrated a relationship between IL-10 and IL-8 (*R*=0.7, *P*<0.0001), and between IL-10 and IL-6 (*R*=0.7, *P*<0.0001). IL-10 was also correlated with IL-1ra (=0.42, *P*<0.001).

Discussion

Cardiac surgery induces systemic inflammatory responses that have been implicated in postoperative organ dysfunction. Recently, the concept of cytokine balance has emerged whereby the balance of pro- and

anti-inflammatory cytokines determine clinical outcome in certain disease states including cardiac surgery. Our previous study showed that IL-6 and IL-8 increased markedly in patients who underwent cardiac surgery with cardiopulmonary bypass. In the present study, changes in anti-inflammatory cytokines were followed in relation to those in pro-inflammatory cytokines. IL-10, IL-6 and IL-8 changed almost similarly. Peak levels appeared 60 min after declamping the aorta, and were followed by a gradual decrease. However, high levels were maintained up to 180 min after declamping. IL-10 correlated with IL-6 and IL-8, suggesting that the increase in IL-10 may be partial compensation for the increased concentration of pro-inflammatory cytokines. IL-1ra increased markedly from 60 min after declamping the aorta. Although peak levels of IL-6, IL-8 and IL-10 appeared at 60 min after declamping, and were followed by a gradual decrease, IL-1ra increased linearly, and peak levels appeared 180 min after declamping the aorta. IL-10 is a potent inhibitor of pro-inflammatory cytokines, suggesting that it may also have an important regulatory role in limiting the duration and extent of the acute inflammatory response.⁹ Furthermore, it has been reported that IL-10 up-regulates IL-1ra and the ability of IL-10 to up-regulate IL-1ra production in PMN may reflect one of the mechanisms underlying the immunosuppressive actions of IL-10.⁵ The present study showed that peak levels of IL-10 appeared 60 min after declamping the aorta, followed by increases in IL-1ra, while the peak production of IL-6 and IL-8 was found 60 min after declamping, and was followed by a decrease. These results indicate that the increased production of IL-10 may have suppressed the production of pro-inflammatory cytokines. It is suggested that IL-10 may exert its anti-inflammatory action by affecting the balance of pro- and anti-inflammatory cytokines. Serum IL-1ra increased considerably which suggests excessive local production of IL-1. IL-1, a monokine produced primarily by macrophages, is known to be involved in the host response to injury and infection.¹¹ Although inflammatory processes are defence mechanisms, IL-1 may cause tissue damage, including stimulation of TNF- α , IL-8 and IL-6, and may contribute to chronic inflammation in unregulated conditions. The action of IL-1 can be controlled in several ways, such as by regulation of its synthesis,¹² by the release of soluble IL-1 receptors,¹³ or by the production of IL-1ra, an antagonistic inhibitor that blocks IL-1 binding to its receptor,¹⁴ thereby effectively preventing the biological actions of IL-1.¹⁵ IL-1ra is a 23- to 25-KD glycosylated protein, originally purified from supernatants

of human monocytes cultured on immune complex-coated surfaces,¹⁴ or from the urine of patients with monocytic leukaemia, which has been recently cloned.¹⁶ The IL-1ra specifically blocks IL-1 β and IL-1 β at its receptor level.¹⁷ The excessive production of IL-6 and IL-8 may be inhibited by suppression of this excessive local production of IL-1. It may be reasonable to retain a physiological state that suppressive cytokines such as IL-1ra and IL-10 increase according to the increased production of IL-8 and IL-6 during cardiac surgery.

These findings suggest that inflammatory cytokines and their suppressive cytokines increase but maintain their balance during cardiac surgery. The inflammatory response to cardiac surgery is thought to be produced by exposing patients to pro-inflammatory trigger factors. These include exposure of blood to the foreign surface of the cardiopulmonary bypass apparatus, myocardial reperfusion after declamping the aorta, reduction in pulmonary blood flow during aortic cross-clamping, and the surgical stress response. In the present study, The production of cytokines did not increase 60 min after clamping the aorta, but increased considerably 60 min after declamping. In addition, in a previous study we showed that these changes correlated with the duration of aortic clamping and cardiopulmonary bypass time. These results suggest that the production of cytokines was related to reperfusion injury in the lungs and myocardium following ischaemia and to invasion due to long lasting cardiopulmonary bypass. In summary, our study extends the results of other investigations¹⁸⁻²⁰ regarding the balance of pro- and anti-inflammatory cytokines. If the balance breaks, the consequences may include myocardial damage and organ failure. Thus, it is necessary to determine the critical level for the ratio of inflammatory and suppressive cytokines. Then, IL-10 and IL-1ra may be useful as a therapeutic agent for the treatment of myocardial injury.

References

- 1 Butler J, Chong GL, Baigrie RJ, Pillai R, Westaby S, Ricker GM. Cytokine responses to cardiopulmonary bypass with membrane and bubble oxygenation. *Ann Thorac Surg* 1992; 53: 833-8.
- 2 Kawamura T, Wakusawa R, Okada K, Inada K. Elevation of cytokines during open heart surgery with cardiopulmonary bypass: participation of interleukin 8 and 6 in reperfusion injury. *Can J Anaesth* 1993; 40: 1016-21.
- 3 Paccard J-P, Shifferli JA, Baggiolini M. NAP-1/IL-8 induces up-regulation of CR1 receptors in human

- neutrophil leukocytes. *Biochem Biophys Res Comm* 1990; 166: 187-92.
- 4 *Fiorentino DF, Bond MW, Mosmann TR*. Two types of mouse T helper cell. IV Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. *J Exp Med* 1989; 170: 2081-95.
 - 5 *Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR*. Interleukin-10. *Annu Rev Immunol* 1993; 11: 165-90.
 - 6 *Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A*. IL-10 inhibits cytokine production by activated macrophages. *J Immunol* 1991; 147: 3815-22.
 - 7 *Tanigawa H, Sone S, Sugihara K, Tanaka K, Ogura T*. Interleukin 4 down-regulates interleukin-6 production by human alveolar macrophages at protein and mRNA levels. *Microbiol Immunol* 1991; 35: 879-93.
 - 8 *Sone S, Yanagawa H, Nishioka Y, et al*. Interleukin-4 as potent down-regulator for human alveolar macrophages capable of producing tumour necrosis factor- and interleukin-1. *Eur Respir J* 1992; 5: 174-81.
 - 9 *Cassatella MA, Meda L, Bonora S, Ceska M, Constantin G*. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 in mediating the production of IL-8 triggered by lipopolysaccharide. *J Exp Med* 1993; 178: 2207-11.
 - 10 *Cassatella MA, Meda L, Gasperini S, Calzetti F, Bonora S*. Interleukin 10 (IL-10) up-regulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation. *J Exp Med* 1994; 179: 1695-9.
 - 11 *Dinarello CA*. Biology of Interleukin 1. *FASEB J* 1988; 2: 108-15.
 - 12 *Kern JA, Lamb RJ, Reed JC, Daniele RP, Nowell PC*. Dexamethasone inhibition of interleukin 1 beta production by human monocytes. Post-transcriptional mechanisms. *J Clinical Invest* 1988; 81: 237-44.
 - 13 *Colotta F, Re F, Muzio M, et al*. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. *Science* 1993; 261: 472-5.
 - 14 *Arend WP, Joslin FG, Massoni RJ*. Effects of immune complexes on production by human monocytes of interleukin 1 or an interleukin 1 inhibitor. *J Immunol* 1985; 134: 3868-75.
 - 15 *Dinarello CA, Wolff SM*. The role of Interleukin -1 in disease. *N Engl J Med* 1993; 328: 106-13.
 - 16 *Eisenberg SP, Evans RJ, Arend WP, et al*. Primary structure and functional expression from complementary DNA of a human interleukin 1 receptor antagonist. *Nature* 1990; 343: 341-6.
 - 17 *Seckinger P, Lowenthal JW, Williamson K, Dayer J-M, MacDonald HR*. A urine inhibitor of interleukin 1 activity that blocks ligand binding. *J Immunol* 1987; 139: 1546-9.
 - 18 *McBride WT, Armstrong MA, Crockard AD, McMurray TJ, Rea JM*. Cytokine balance and immunosuppressive changes at cardiac surgery : contrasting response between patients and isolated CPB circuits. *Br J Anaesth* 1995; 75: 724-33.
 - 19 *Girardin E, Roux-Lombard P, Grau GE, et al*. Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. *Immunology* 1992; 76: 20-3.
 - 20 *Miller LC, Lynch EA, Isa S, Logan JW, Dinarello CA, Steere AC*. Balance of synovial fluid IL-1 and IL-1 receptor antagonist and recovery from Lyme arthritis. *Lancet* 1993; 341: 146-8.